Drug Discovery Targeting Bromodomain-Containing Protein 4

Journal of Medicinal Chemistry

Volumn 60, Issue 11, 2017, Pages 4533-4558

  Liu, Zhiqing ^a   Wang, Pingyuan ^a   Chen, Haiying ^a   Wold, Eric A ^a   Tian, Bing ^a,b   Brasier, Allan R ^a,b   Zhou, Jia ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN 4; BROMODOMAIN INHIBITOR; HISTONE ACETYLTRANSFERASE; PROTEIN DERIVATIVE; RNA POLYMERASE II; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

CYTOKINE PRODUCTION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; CHEMISTRY; DRUG DEVELOPMENT;

DRUG DISCOVERY; HUMANS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 85020397055     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01761     Document Type: Review

References (200)

1. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705 10.1016/j.cell.2007.02.005
2. Li, B.; Carey, M.; Workman, J. L. The role of chromatin during transcription Cell 2007, 128, 707-719 10.1016/j.cell.2007.01.015
3. Qiu, J. Epigenetics: unfinished symphony Nature 2006, 441, 143-145 10.1038/441143a
4. Bannister, A. J.; Kouzarides, T. Regulation of chromatin by histone modifications Cell Res. 2011, 21, 381-395 10.1038/cr.2011.22
5. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400 10.1038/nrd3674
6. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications Nature 2000, 403, 41-45 10.1038/47412
7. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009, 325, 834-840 10.1126/science.1175371
8. Hewings, D. S.; Rooney, T. P.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions J. Med. Chem. 2012, 55, 9393-9413 10.1021/jm300915b
9. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO. J. 2000, 19, 1176-1179 10.1093/emboj/19.6.1176
10. Devaiah, B. N.; Case-Borden, C.; Gegonne, A.; Hsu, C. H.; Chen, Q.; Meerzaman, D.; Dey, A.; Ozato, K.; Singer, D. S. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin Nat. Struct. Mol. Biol. 2016, 23, 540-548 10.1038/nsmb.3228
11. Zeng, L.; Zhou, M. M. Bromodomain: an acetyl-lysine binding domain FEBS Lett. 2002, 513, 124-128 10.1016/S0014-5793(01)03309-9
12. Lange, M.; Kaynak, B.; Forster, U. B.; Tonjes, M.; Fischer, J. J.; Grimm, C.; Schlesinger, J.; Just, S.; Dunkel, I.; Krueger, T.; Mebus, S.; Lehrach, H.; Lurz, R.; Gobom, J.; Rottbauer, W.; Abdelilah-Seyfried, S.; Sperling, S. Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex Genes Dev. 2008, 22, 2370-2384 10.1101/gad.471408
13. Zeng, L.; Zhang, Q.; Li, S.; Plotnikov, A. N.; Walsh, M. J.; Zhou, M. M. Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b Nature 2010, 466, 258-262 10.1038/nature09139
14. Su, D.; Hu, Q.; Li, Q.; Thompson, J. R.; Cui, G.; Fazly, A.; Davies, B. A.; Botuyan, M. V.; Zhang, Z.; Mer, G. Structural basis for recognition of H3K56-acetylated histone H3-H4 by the chaperone Rtt106 Nature 2012, 483, 104-107 10.1038/nature10861
15. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 2014, 13, 337-356 10.1038/nrd4286
16. Chiang, C. M. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4 F1000Prime Rep. 2009, 1, 98 10.3410/B1-98
17. Dey, A.; Chitsaz, F.; Abbasi, A.; Misteli, T.; Ozato, K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 8758-8763 10.1073/pnas.1433065100
18. Romero, F. A.; Taylor, A. M.; Crawford, T. D.; Tsui, V.; Cote, A.; Magnuson, S. Disrupting acetyl-lysine recognition: Progress in the development of bromodomain inhibitors J. Med. Chem. 2016, 59, 1271-1298 10.1021/acs.jmedchem.5b01514
19. Ghoshal, A.; Yugandhar, D.; Srivastava, A. K. BET inhibitors in cancer therapeutics: a patent review Expert Opin. Ther. Pat. 2016, 26, 505-522 10.1517/13543776.2016.1159299
20. Yu, L.; Wang, Z.; Zhang, Z.; Ren, X.; Lu, X.; Ding, K. Small-molecule BET inhibitors in clinical and preclinical development and their therapeutic potential Curr. Top. Med. Chem. 2015, 15, 776-794 10.2174/1568026615666150302110135
21. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites J. Med. Chem. 2012, 55, 7346-7359 10.1021/jm300346w
22. Dhalluin, C.; Carlson, J. E.; Zeng, L.; He, C.; Aggarwal, A. K.; Zhou, M.-M. Structure and ligand of a histone acetyltransferase bromodomain Nature 1999, 399, 491-496 10.1038/20974
23. Fukazawa, H.; Masumi, A. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal Biol. Pharm. Bull. 2012, 35, 2064-2068 10.1248/bpb.b12-00527
24. Jones, M. H.; Numata, M.; Shimane, M. Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh Genomics 1997, 45, 529-534 10.1006/geno.1997.5000
25. Shang, E.; Nickerson, H. D.; Wen, D.; Wang, X.; Wolgemuth, D. J. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation Development 2007, 134, 3507-3515 10.1242/dev.004481
26. Zhou, Q.; Li, T.; Price, D. H. RNA polymerase II elongation control Annu. Rev. Biochem. 2012, 81, 119-143 10.1146/annurev-biochem-052610-095910
27. Rahman, S.; Sowa, M. E.; Ottinger, M.; Smith, J. A.; Shi, Y.; Harper, J. W.; Howley, P. M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3 Mol. Cell. Biol. 2011, 31, 2641-2652 10.1128/MCB.01341-10
28. Lamonica, J. M.; Deng, W.; Kadauke, S.; Campbell, A. E.; Gamsjaeger, R.; Wang, H.; Cheng, Y.; Billin, A. N.; Hardison, R. C.; Mackay, J. P.; Blobel, G. A. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes Proc. Natl. Acad. Sci. U. S. A. 2011, 108, E159-168 10.1073/pnas.1102140108
29. Gamsjaeger, R.; Webb, S. R.; Lamonica, J. M.; Billin, A.; Blobel, G. A.; Mackay, J. P. Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3 Mol. Cell. Biol. 2011, 31, 2632-2640 10.1128/MCB.05413-11
30. Peng, J.; Dong, W.; Chen, L.; Zou, T.; Qi, Y.; Liu, Y. Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation Mol. Cell. Biochem. 2007, 294, 45-54 10.1007/s11010-006-9223-6
31. Prinjha, R. K.; Witherington, J.; Lee, K. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 2012, 33, 146-153 10.1016/j.tips.2011.12.002
32. Picaud, S.; Wells, C.; Felletar, I.; Brotherton, D.; Martin, S.; Savitsky, P.; Diez-Dacal, B.; Philpott, M.; Bountra, C.; Lingard, H.; Fedorov, O.; Muller, S.; Brennan, P. E.; Knapp, S.; Filippakopoulos, P. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 19754-19759 10.1073/pnas.1310658110
33. Mirguet, O.; Gosmini, R.; Toum, J.; Clement, C. A.; Barnathan, M.; Brusq, J. M.; Mordaunt, J. E.; Grimes, R. M.; Crowe, M.; Pineau, O.; Ajakane, M.; Daugan, A.; Jeffrey, P.; Cutler, L.; Haynes, A. C.; Smithers, N. N.; Chung, C. W.; Bamborough, P.; Uings, I. J.; Lewis, A.; Witherington, J.; Parr, N.; Prinjha, R. K.; Nicodeme, E. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains J. Med. Chem. 2013, 56, 7501-7515 10.1021/jm401088k
34. Coude, M. M.; Braun, T.; Berrou, J.; Dupont, M.; Bertrand, S.; Masse, A.; Raffoux, E.; Itzykson, R.; Delord, M.; Riveiro, M. E.; Herait, P.; Baruchel, A.; Dombret, H.; Gardin, C. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells Oncotarget 2015, 6, 17698-17712 10.18632/oncotarget.4131
35. Siu, K. T.; Eda, H.; Santo, L.; Ramachandran, J.; Koulnis, M.; Mertz, J.; Sims, R. J.; Cooper, M.; Raje, N. S. Effect of the BET inhibitor, Cpi-0610, alone and in combination with lenalidomide in multiple myeloma Blood 2015, 126, 4255-4255
36. Shapiro, G. I.; Dowlati, A.; LoRusso, P. M.; Eder, J. P.; Anderson, A.; Do, K. T.; Kagey, M. H.; Sirard, C.; Bradner, J. E.; Landau, S. B. Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC) Mol. Cancer Ther. 2015, 14, A49-A49 10.1158/1535-7163.TARG-15-A49
37. Sarthy, A.; Li, L.; Albert, D. H.; Lin, X.; Scott, W.; Faivre, E.; Bui, M. H.; Huang, X.; Wilcox, D. M.; Magoc, T.; Buchanan, F. G.; Tapang, P.; Sheppard, G. S.; Wang, L.; Fidanze, S. D.; Pratt, J.; Liu, D.; Hasvold, L.; Hessler, P.; Uziel, T.; Lam, L.; Rajaraman, G.; Fang, G.; Elmore, S. W.; Rosenberg, S. H.; McDaniel, K.; Kati, W.; Shen, Y. Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications Cancer Res. 2016, 76, 4718-4718 10.1158/1538-7445.AM2016-4718
38. Belkina, A. C.; Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer Nat. Rev. Cancer 2012, 12, 465-477 10.1038/nrc3256
39. Padmanabhan, B.; Mathur, S.; Manjula, R.; Tripathi, S. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases J. Biosci. 2016, 41, 295-311 10.1007/s12038-016-9600-6
40. Tontsch-Grunt, U.; Savarese, F.; Gerlach, D.; Gianni, D.; Baum, A.; Scharn, D.; Engelhardt, H.; Kaya, O.; Schweifer, N.; Gerstberger, T.; Kraut, N. Abstract B79: BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes Mol. Cancer Ther. 2015, 14, B79 10.1158/1535-7163.TARG-15-B79
41. Study of BMS-986158 in subjects with select advanced solid tumors (BET). Clinical trials, 2 April, 2015; https://clinicaltrials.gov/ct2/show/NCT02419417.
42. Millan, D. S.; Alvarez Morales, M. A.; Barr, K. J.; Cardillo, D.; Collis, A.; Dinsmore, C. J.; Escobedo, J. A.; Foley, K. P.; Herbertz, T.; Hubbs, S.; Kauffman, G. S.; Kayser-Bricker, K. J.; Kershaw, M. T.; Luke, G. P.; Martin, M. W.; McKinnon, C.; Mendes, R. L.; Muskiewicz, K. R.; Schiller, S. E. R.; Soulard, P.; Talbot, A. C.; Walker, D.; Yao, L.; Williams, G. L. FT-1101: A structurally distinct pan-BET bromodomain inhibitor with activity in preclinical models of hematologic malignancies Blood 2015, 126, 1367
43. Liu, P. C. C.; Liu, X. M.; Stubbs, M. C.; Maduskuie, T.; Sparks, R.; Zolotarjova, N.; Li, J.; Wen, X.; Favata, M.; Feldman, P.; Volgina, A.; DiMatteo, D.; Collins, R.; Falahatpisheh, N.; Polam, P.; Li, Y.; Covington, M.; Diamond-Fosbenner, S.; Wynn, R.; Burn, T.; Vaddi, K.; Yeleswaram, S.; Combs, A. P.; Yao, W.; Huber, R.; Scherle, P.; Hollis, G. Abstract 3523: Discovery of a novel BET inhibitor INCB054329 Cancer Res. 2015, 75, 3523 10.1158/1538-7445.AM2015-3523
44. Dose escalation study of GSK2820151 in subjects with advanced or recurrent solid tumors. Clinical trials, 30 November, 2015; https://clinicaltrials.gov/ct2/show/NCT02630251.
45. Attwell, S.; Campeau, E.; Jahagirdar, R.; Kharenko, O.; Norek, K.; Tsujikawa, L.; Calosing, C.; Patel, R.; Gesner, E.; Lakhotia, S.; Hansen, H. Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies Mol. Cancer Ther. 2015, 14, C86 10.1158/1535-7163.TARG-15-C86
46. Bates, J.; Kusam, S.; Tannheimer, S.; Chan, J.; Li, Y.; Breckenridge, D.; Tumas, D. The combination of a BET inhibitor (GS-5829) and a BTK Inhibitor (GS-4059) potentiates DLBCL cell line cell death and reduces expression of MYC, IL-10, and IL-6 in vitro Blood 2016, 128, 5116
47. Gjoksi, B.; Ghayor, C.; Bhattacharya, I.; Zenobi-Wong, M.; Weber, F. E. The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model Clin. Epigenet. 2016, 8, 42 10.1186/s13148-016-0209-2
48. Jiang, Y. W.; Veschambre, P.; Erdjument-Bromage, H.; Tempst, P.; Conaway, J. W.; Conaway, R. C.; Kornberg, R. D. Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 8538-8543 10.1073/pnas.95.15.8538
49. Floyd, S. R.; Pacold, M. E.; Huang, Q.; Clarke, S. M.; Lam, F. C.; Cannell, I. G.; Bryson, B. D.; Rameseder, J.; Lee, M. J.; Blake, E. J.; Fydrych, A.; Ho, R.; Greenberger, B. A.; Chen, G. C.; Maffa, A.; Del Rosario, A. M.; Root, D. E.; Carpenter, A. E.; Hahn, W. C.; Sabatini, D. M.; Chen, C. C.; White, F. M.; Bradner, J. E.; Yaffe, M. B. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling Nature 2013, 498, 246-250 10.1038/nature12147
50. Wu, S. Y.; Chiang, C. M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation J. Biol. Chem. 2007, 282, 13141-13145 10.1074/jbc.R700001200
51. Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J. P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Muller, S.; Pawson, T.; Gingras, A. C.; Arrowsmith, C. H.; Knapp, S. Histone recognition and large-scale structural analysis of the human bromodomain family Cell 2012, 149, 214-231 10.1016/j.cell.2012.02.013
52. Shi, J.; Wang, Y.; Zeng, L.; Wu, Y.; Deng, J.; Zhang, Q.; Lin, Y.; Li, J.; Kang, T.; Tao, M.; Rusinova, E.; Zhang, G.; Wang, C.; Zhu, H.; Yao, J.; Zeng, Y. X.; Evers, B. M.; Zhou, M. M.; Zhou, B. P. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer Cancer Cell 2014, 25, 210-225 10.1016/j.ccr.2014.01.028
53. Vollmuth, F.; Blankenfeldt, W.; Geyer, M. Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution J. Biol. Chem. 2009, 284, 36547-36556 10.1074/jbc.M109.033712
54. Chung, C. W.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J. M.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clement, C. A.; Boullay, A. B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and characterization of small molecule inhibitors of the BET family bromodomains J. Med. Chem. 2011, 54, 3827-3838 10.1021/jm200108t
55. Kanno, T.; Kanno, Y.; Siegel, R. M.; Jang, M. K.; Lenardo, M. J.; Ozato, K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells Mol. Cell 2004, 13, 33-43 10.1016/S1097-2765(03)00482-9
56. Dey, A.; Nishiyama, A.; Karpova, T.; McNally, J.; Ozato, K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription Mol. Biol. Cell 2009, 20, 4899-4909 10.1091/mbc.E09-05-0380
57. Dey, A.; Ellenberg, J.; Farina, A.; Coleman, A. E.; Maruyama, T.; Sciortino, S.; Lippincott-Schwartz, J.; Ozato, K. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition Mol. Cell. Biol. 2000, 20, 6537-6549 10.1128/MCB.20.17.6537-6549.2000
58. You, J.; Li, Q.; Wu, C.; Kim, J.; Ottinger, M.; Howley, P. M. Regulation of aurora B expression by the bromodomain protein Brd4 Mol. Cell. Biol. 2009, 29, 5094-5103 10.1128/MCB.00299-09
59. Anand, P.; Brown, J. D.; Lin, C. Y.; Qi, J.; Zhang, R.; Artero, P. C.; Alaiti, M. A.; Bullard, J.; Alazem, K.; Margulies, K. B.; Cappola, T. P.; Lemieux, M.; Plutzky, J.; Bradner, J. E.; Haldar, S. M. BET bromodomains mediate transcriptional pause release in heart failure Cell 2013, 154, 569-582 10.1016/j.cell.2013.07.013
60. Korb, E.; Herre, M.; Zucker-Scharff, I.; Darnell, R. B.; Allis, C. D. BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice Nat. Neurosci. 2015, 18, 1464-1473 10.1038/nn.4095
61. Peng, J.; Zhu, Y.; Milton, J. T.; Price, D. H. Identification of multiple cyclin subunits of human P-TEFb Genes Dev. 1998, 12, 755-762 10.1101/gad.12.5.755
62. Yang, Z.; Yik, J. H.; Chen, R.; He, N.; Jang, M. K.; Ozato, K.; Zhou, Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4 Mol. Cell 2005, 19, 535-545 10.1016/j.molcel.2005.06.029
63. Jang, M. K.; Mochizuki, K.; Zhou, M.; Jeong, H. S.; Brady, J. N.; Ozato, K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription Mol. Cell 2005, 19, 523-534 10.1016/j.molcel.2005.06.027
64. Yang, Z.; He, N.; Zhou, Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression Mol. Cell. Biol. 2008, 28, 967-976 10.1128/MCB.01020-07
65. French, C. A.; Miyoshi, I.; Kubonishi, I.; Grier, H. E.; Perez-Atayde, A. R.; Fletcher, J. A. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma Cancer Res. 2003, 63, 304-307
66. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917 10.1016/j.cell.2011.08.017
67. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J., 3rd Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 16669-16674 10.1073/pnas.1108190108
68. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073 10.1038/nature09504
69. Asangani, I. A.; Dommeti, V. L.; Wang, X.; Malik, R.; Cieslik, M.; Yang, R.; Escara-Wilke, J.; Wilder-Romans, K.; Dhanireddy, S.; Engelke, C.; Iyer, M. K.; Jing, X.; Wu, Y. M.; Cao, X.; Qin, Z. S.; Wang, S.; Feng, F. Y.; Chinnaiyan, A. M. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Nature 2014, 510, 278-282 10.1038/nature13229
70. Segura, M. F.; Fontanals-Cirera, B.; Gaziel-Sovran, A.; Guijarro, M. V.; Hanniford, D.; Zhang, G.; Gonzalez-Gomez, P.; Morante, M.; Jubierre, L.; Zhang, W.; Darvishian, F.; Ohlmeyer, M.; Osman, I.; Zhou, M. M.; Hernando, E. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy Cancer Res. 2013, 73, 6264-6276 10.1158/0008-5472.CAN-13-0122-T
71. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528 10.1038/nature10334
72. Baratta, M. G.; Schinzel, A. C.; Zwang, Y.; Bandopadhayay, P.; Bowman-Colin, C.; Kutt, J.; Curtis, J.; Piao, H.; Wong, L. C.; Kung, A. L.; Beroukhim, R.; Bradner, J. E.; Drapkin, R.; Hahn, W. C.; Liu, J. F.; Livingston, D. M. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 232-237 10.1073/pnas.1422165112
73. Ceribelli, M.; Kelly, P. N.; Shaffer, A. L.; Wright, G. W.; Xiao, W.; Yang, Y.; Mathews Griner, L. A.; Guha, R.; Shinn, P.; Keller, J. M.; Liu, D.; Patel, P. R.; Ferrer, M.; Joshi, S.; Nerle, S.; Sandy, P.; Normant, E.; Thomas, C. J.; Staudt, L. M. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 11365-11370 10.1073/pnas.1411701111
74. Puissant, A.; Frumm, S. M.; Alexe, G.; Bassil, C. F.; Qi, J.; Chanthery, Y. H.; Nekritz, E. A.; Zeid, R.; Gustafson, W. C.; Greninger, P.; Garnett, M. J.; McDermott, U.; Benes, C. H.; Kung, A. L.; Weiss, W. A.; Bradner, J. E.; Stegmaier, K. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discovery 2013, 3, 308-323 10.1158/2159-8290.CD-12-0418
75. Lockwood, W. W.; Zejnullahu, K.; Bradner, J. E.; Varmus, H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 19408-19413 10.1073/pnas.1216363109
76. Huang, B.; Yang, X. D.; Zhou, M. M.; Ozato, K.; Chen, L. F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA Mol. Cell. Biol. 2009, 29, 1375-1387 10.1128/MCB.01365-08
77. Chen, L. F.; Mu, Y.; Greene, W. C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB EMBO. J. 2002, 21, 6539-6548 10.1093/emboj/cdf660
78. Ding, N.; Hah, N.; Yu, R. T.; Sherman, M. H.; Benner, C.; Leblanc, M.; He, M.; Liddle, C.; Downes, M.; Evans, R. M. BRD4 is a novel therapeutic target for liver fibrosis Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 15713-15718 10.1073/pnas.1522163112
79. Tian, B.; Zhao, Y.; Sun, H.; Zhang, Y.; Yang, J.; Brasier, A. R. BRD4 mediates NFkB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation Am. J. Physiol. 2016, 311, L1183 10.1152/ajplung.00224.2016
80. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123 10.1038/nature09589
81. Khan, Y. M.; Kirkham, P.; Barnes, P. J.; Adcock, I. M. Brd4 is essential for IL-1beta-induced inflammation in human airway epithelial cells PLoS One 2014, 9, e95051 10.1371/journal.pone.0095051
82. Tang, X.; Peng, R.; Phillips, J. E.; Deguzman, J.; Ren, Y.; Apparsundaram, S.; Luo, Q.; Bauer, C. M.; Fuentes, M. E.; DeMartino, J. A.; Tyagi, G.; Garrido, R.; Hogaboam, C. M.; Denton, C. P.; Holmes, A. M.; Kitson, C.; Stevenson, C. S.; Budd, D. C. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis Am. J. Pathol. 2013, 183, 470-479 10.1016/j.ajpath.2013.04.020
83. Tang, X.; Peng, R.; Ren, Y.; Apparsundaram, S.; Deguzman, J.; Bauer, C. M.; Hoffman, A. F.; Hamilton, S.; Liang, Z.; Zeng, H.; Fuentes, M. E.; Demartino, J. A.; Kitson, C.; Stevenson, C. S.; Budd, D. C. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis Mol. Pharmacol. 2013, 83, 283-293 10.1124/mol.112.081661
84. Bailey, D.; Jahagirdar, R.; Gordon, A.; Hafiane, A.; Campbell, S.; Chatur, S.; Wagner, G. S.; Hansen, H. C.; Chiacchia, F. S.; Johansson, J.; Krimbou, L.; Wong, N. C.; Genest, J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J. Am. Coll. Cardiol. 2010, 55, 2580-2589 10.1016/j.jacc.2010.02.035
85. Jahagirdar, R.; Zhang, H.; Azhar, S.; Tobin, J.; Attwell, S.; Yu, R.; Wu, J.; McLure, K. G.; Hansen, H. C.; Wagner, G. S.; Young, P. R.; Srivastava, R. A.; Wong, N. C.; Johansson, J. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice Atherosclerosis 2014, 236, 91-100 10.1016/j.atherosclerosis.2014.06.008
86. Spiltoir, J. I.; Stratton, M. S.; Cavasin, M. A.; Demos-Davies, K.; Reid, B. G.; Qi, J.; Bradner, J. E.; McKinsey, T. A. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy J. Mol. Cell. Cardiol. 2013, 63, 175-179 10.1016/j.yjmcc.2013.07.017
87. Sartor, G. C.; Powell, S. K.; Brothers, S. P.; Wahlestedt, C. Epigenetic readers of lysine acetylation regulate cocaine-induced plasticity J. Neurosci. 2015, 35, 15062-15072 10.1523/JNEUROSCI.0826-15.2015
88. Gacias, M.; Gerona-Navarro, G.; Plotnikov, A. N.; Zhang, G.; Zeng, L.; Kaur, J.; Moy, G.; Rusinova, E.; Rodriguez, Y.; Matikainen, B.; Vincek, A.; Joshua, J.; Casaccia, P.; Zhou, M. M. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression Chem. Biol. 2014, 21, 841-854 10.1016/j.chembiol.2014.05.009
89. Zhou, M.; Huang, K.; Jung, K. J.; Cho, W. K.; Klase, Z.; Kashanchi, F.; Pise-Masison, C. A.; Brady, J. N. Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29 J. Virol. 2009, 83, 1036-1044 10.1128/JVI.01316-08
90. Lin, A.; Wang, S.; Nguyen, T.; Shire, K.; Frappier, L. The EBNA1 protein of Epstein-Barr virus functionally interacts with Brd4 J. Virol. 2008, 82, 12009-12019 10.1128/JVI.01680-08
91. Gagnon, D.; Joubert, S.; Senechal, H.; Fradet-Turcotte, A.; Torre, S.; Archambault, J. Proteasomal degradation of the papillomavirus E2 protein is inhibited by overexpression of bromodomain-containing protein 4 J. Virol. 2009, 83, 4127-4139 10.1128/JVI.02468-08
92. Wu, S. Y.; Lee, A. Y.; Hou, S. Y.; Kemper, J. K.; Erdjument-Bromage, H.; Tempst, P.; Chiang, C. M. Brd4 links chromatin targeting to HPV transcriptional silencing Genes Dev. 2006, 20, 2383-2396 10.1101/gad.1448206
93. You, J.; Croyle, J. L.; Nishimura, A.; Ozato, K.; Howley, P. M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes Cell 2004, 117, 349-360 10.1016/S0092-8674(04)00402-7
94. Boehm, D.; Conrad, R. J.; Ott, M. Bromodomain proteins in HIV infection Viruses 2013, 5, 1571-1586 10.3390/v5061571
95. Bisgrove, D. A.; Mahmoudi, T.; Henklein, P.; Verdin, E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 13690-13695 10.1073/pnas.0705053104
96. Zhu, J.; Gaiha, G. D.; John, S. P.; Pertel, T.; Chin, C. R.; Gao, G.; Qu, H.; Walker, B. D.; Elledge, S. J.; Brass, A. L. Reactivation of latent HIV-1 by inhibition of BRD4 Cell Rep. 2012, 2, 807-816 10.1016/j.celrep.2012.09.008
97. Lu, P.; Qu, X.; Shen, Y.; Jiang, Z.; Wang, P.; Zeng, H.; Ji, H.; Deng, J.; Yang, X.; Li, X.; Lu, H.; Zhu, H. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb Sci. Rep. 2016, 6, 24100 10.1038/srep24100
98. Banerjee, C.; Archin, N.; Michaels, D.; Belkina, A. C.; Denis, G. V.; Bradner, J.; Sebastiani, P.; Margolis, D. M.; Montano, M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 J. Leukocyte Biol. 2012, 92, 1147-1154 10.1189/jlb.0312165
99. Boehm, D.; Calvanese, V.; Dar, R. D.; Xing, S.; Schroeder, S.; Martins, L.; Aull, K.; Li, P. C.; Planelles, V.; Bradner, J. E.; Zhou, M. M.; Siliciano, R. F.; Weinberger, L.; Verdin, E.; Ott, M. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism Cell Cycle 2013, 12, 452-462 10.4161/cc.23309
100. Li, Z.; Guo, J.; Wu, Y.; Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation Nucleic Acids Res. 2013, 41, 277-287 10.1093/nar/gks976
101. Archin, N. M.; Liberty, A. L.; Kashuba, A. D.; Choudhary, S. K.; Kuruc, J. D.; Crooks, A. M.; Parker, D. C.; Anderson, E. M.; Kearney, M. F.; Strain, M. C.; Richman, D. D.; Hudgens, M. G.; Bosch, R. J.; Coffin, J. M.; Eron, J. J.; Hazuda, D. J.; Margolis, D. M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 2012, 487, 482-485 10.1038/nature11286
102. Miyoshi, S.; Ooike, S.; Iwata, K.; Hikawa, H.; Sugahara, K. Antitumor agents. WO2009084693, 2009.
103. Nasveschuk, C. G.; Audia, J. E.; Leblanc, Y.; Hewitt, M. C.; Côté, A.; Vaswani, R. G.; Albrecht, B. K.; Taylor, A. M.; Harmange, J. C.; Gehling, V. S. Bromodomain inhibitors and uses thereof. US08796261, 2010.
104. Jang, J. E.; Eom, J. I.; Jeung, H. K.; Cheong, J. W.; Lee, J. Y.; Kim, J. S.; Min, Y. H. AMPK-ULK1-mediated autophagy confers resistance to BET inhibitor JQ1 in acute myeloid leukemia stem cells Clin. Cancer Res. 2016, 1-39 10.1158/1078-0432.CCR-16-1903
105. Yokoyama, Y.; Zhu, H.; Lee, J. H.; Kossenkov, A. V.; Wu, S. Y.; Wickramasinghe, J. M.; Yin, X.; Palozola, K. C.; Gardini, A.; Showe, L. C.; Zaret, K. S.; Liu, Q.; Speicher, D.; Conejo-Garcia, J. R.; Bradner, J. E.; Zhang, Z.; Sood, A. K.; Ordog, T.; Bitler, B. G.; Zhang, R. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer Cancer Res. 2016, 76, 6320-6330 10.1158/0008-5472.CAN-16-0854
106. da Motta, L. L.; Ledaki, I.; Purshouse, K.; Haider, S.; De Bastiani, M. A.; Baban, D.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; Li, J. L.; Knapp, S.; Ebner, D.; Klamt, F.; Harris, A. L.; McIntyre, A. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer Oncogene 2017, 36, 122 10.1038/onc.2016.184
107. Krugmann, S.; Anderson, K. E.; Ridley, S. H.; Risso, N.; McGregor, A.; Coadwell, J.; Davidson, K.; Eguinoa, A.; Ellson, C. D.; Lipp, P.; Manifava, M.; Ktistakis, N.; Painter, G.; Thuring, J. W.; Cooper, M. A.; Lim, Z. Y.; Holmes, A. B.; Dove, S. K.; Michell, R. H.; Grewal, A.; Nazarian, A.; Erdjument-Bromage, H.; Tempst, P.; Stephens, L. R.; Hawkins, P. T. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices Mol. Cell 2002, 9, 95-108 10.1016/S1097-2765(02)00434-3
108. Conway, S. J.; Gardiner, J.; Grove, S. J.; Johns, M. K.; Lim, Z. Y.; Painter, G. F.; Robinson, D. E.; Schieber, C.; Thuring, J. W.; Wong, L. S.; Yin, M. X.; Burgess, A. W.; Catimel, B.; Hawkins, P. T.; Ktistakis, N. T.; Stephens, L. R.; Holmes, A. B. Synthesis and biological evaluation of phosphatidylinositol phosphate affinity probes Org. Biomol. Chem. 2010, 8, 66-76 10.1039/B913399B
109. Zhao, Y.; Yang, C. Y.; Wang, S. The making of I-BET762, a BET bromodomain inhibitor now in clinical development J. Med. Chem. 2013, 56, 7498-7500 10.1021/jm4014407
110. Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Leblanc, Y.; Cote, A.; Nasveschuk, C. G.; Taylor, A. M.; Harmange, J. C.; Audia, J. E.; Pardo, E.; Joshi, S.; Sandy, P.; Mertz, J. A.; Sims, R. J., 3rd; Bergeron, L.; Bryant, B. M.; Bellon, S.; Poy, F.; Jayaram, H.; Sankaranarayanan, R.; Yellapantula, S.; Bangalore Srinivasamurthy, N.; Birudukota, S.; Albrecht, B. K. Discovery, design, and optimization of isoxazole azepine BET inhibitors ACS Med. Chem. Lett. 2013, 4, 835-840 10.1021/ml4001485
111. Albrecht, B. K.; Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Cote, A.; Leblanc, Y.; Nasveschuk, C. G.; Bellon, S.; Bergeron, L.; Campbell, R.; Cantone, N.; Cooper, M. R.; Cummings, R. T.; Jayaram, H.; Joshi, S.; Mertz, J. A.; Neiss, A.; Normant, E.; O'Meara, M.; Pardo, E.; Poy, F.; Sandy, P.; Supko, J.; Sims, R. J., 3rd; Harmange, J. C.; Taylor, A. M.; Audia, J. E. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) Family as a candidate for human clinical trials J. Med. Chem. 2016, 59, 1330-1339 10.1021/acs.jmedchem.5b01882
112. Hewitt, M. C.; Leblanc, Y.; Gehling, V. S.; Vaswani, R. G.; Cote, A.; Nasveschuk, C. G.; Taylor, A. M.; Harmange, J. C.; Audia, J. E.; Pardo, E.; Cummings, R.; Joshi, S.; Sandy, P.; Mertz, J. A.; Sims, R. J., 3rd; Bergeron, L.; Bryant, B. M.; Bellon, S.; Poy, F.; Jayaram, H.; Tang, Y.; Albrecht, B. K. Development of methyl isoxazoleazepines as inhibitors of BET Bioorg. Med. Chem. Lett. 2015, 25, 1842-1848 10.1016/j.bmcl.2015.03.045
113. Taylor, A. M.; Vaswani, R. G.; Gehling, V. S.; Hewitt, M. C.; Leblanc, Y.; Audia, J. E.; Bellon, S.; Cummings, R. T.; Cote, A.; Harmange, J. C.; Jayaram, H.; Joshi, S.; Lora, J. M.; Mertz, J. A.; Neiss, A.; Pardo, E.; Nasveschuk, C. G.; Poy, F.; Sandy, P.; Setser, J. W.; Sims, R. J., 3rd; Tang, Y.; Albrecht, B. K. Discovery of benzotriazolo[4,3-d][1,4]diazepines as orally active inhibitors of BET bromodomains ACS Med. Chem. Lett. 2016, 7, 145-150 10.1021/ml500411h
114. Landau, S. B.; Kagey, M. Bromodomain inhibitors. WO2016069578, 2016.
115. Filippakopoulos, P.; Picaud, S.; Fedorov, O.; Keller, M.; Wrobel, M.; Morgenstern, O.; Bracher, F.; Knapp, S. Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family Bioorg. Med. Chem. 2012, 20, 1878-1886 10.1016/j.bmc.2011.10.080
116. Endo, J.; Hikawa, H.; Hamada, M.; Ishibuchi, S.; Fujie, N.; Sugiyama, N.; Tanaka, M.; Kobayashi, H.; Sugahara, K.; Oshita, K.; Iwata, K.; Ooike, S.; Murata, M.; Sumichika, H.; Chiba, K.; Adachi, K. A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor Bioorg. Med. Chem. Lett. 2016, 26, 1365-1370 10.1016/j.bmcl.2016.01.084
117. Schmees, N.; Buchmann, B.; Haendler, B.; Neuhaus, R.; Lejeune, P.; Kruger, M.; Fernandez-Montalvan, A.; Kunzer, H.; Rehwinkel, H. 4-Substituted pyrrolo- and pyrazolo- diazepines. WO2014128111, 2014.
118. Vadivelu, S.; Rajagopal, S.; Chinnapattu, M.; Gondrala, P. K.; Sivanandhan, D.; Mulakala, C. Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer. WO2016157221, 2016.
119. Liu, D.; Pratt, J.; Wang, L.; Hasvold, L. A.; Bogdan, A. Bromodomain inhibitors. US20140256710, 2014.
120. Li, J.; Wang, P.; Zhou, B.; Shi, J.; Liu, J.; Li, X.; Fan, L.; Zheng, Y.; Ouyang, L. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors Eur. J. Med. Chem. 2016, 121, 294-299 10.1016/j.ejmech.2016.05.057
121. Siegel, S.; Baurle, S.; Cleve, A.; Haendler, B.; Fernandez-Montalvan, A.; Monning, U.; Krause, S.; Lejeune, P.; Busemann, M.; Kuhnke, J. Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines. WO2014128067, 2014.
122. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands J. Med. Chem. 2011, 54, 6761-6770 10.1021/jm200640v
123. Hewings, D. S.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, K.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russell, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands J. Med. Chem. 2013, 56, 3217-3227 10.1021/jm301588r
124. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C. W. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides J. Med. Chem. 2012, 55, 587-596 10.1021/jm201283q
125. McKeown, M. R.; Shaw, D. L.; Fu, H.; Liu, S.; Xu, X.; Marineau, J. J.; Huang, Y.; Zhang, X.; Buckley, D. L.; Kadam, A.; Zhang, Z.; Blacklow, S. C.; Qi, J.; Zhang, W.; Bradner, J. E. Biased multicomponent reactions to develop novel bromodomain inhibitors J. Med. Chem. 2014, 57, 9019-9027 10.1021/jm501120z
126. Mirguet, O.; Lamotte, Y.; Donche, F.; Toum, J.; Gellibert, F.; Bouillot, A.; Gosmini, R.; Nguyen, V. L.; Delannee, D.; Seal, J.; Blandel, F.; Boullay, A. B.; Boursier, E.; Martin, S.; Brusq, J. M.; Krysa, G.; Riou, A.; Tellier, R.; Costaz, A.; Huet, P.; Dudit, Y.; Trottet, L.; Kirilovsky, J.; Nicodeme, E. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151 Bioorg. Med. Chem. Lett. 2012, 22, 2963-2967 10.1016/j.bmcl.2012.01.125
127. Seal, J.; Lamotte, Y.; Donche, F.; Bouillot, A.; Mirguet, O.; Gellibert, F.; Nicodeme, E.; Krysa, G.; Kirilovsky, J.; Beinke, S.; McCleary, S.; Rioja, I.; Bamborough, P.; Chung, C. W.; Gordon, L.; Lewis, T.; Walker, A. L.; Cutler, L.; Lugo, D.; Wilson, D. M.; Witherington, J.; Lee, K.; Prinjha, R. K. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 2012, 22, 2968-2972 10.1016/j.bmcl.2012.02.041
128. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533 10.1038/nature10509
129. Ran, X.; Zhao, Y.; Liu, L.; Bai, L.; Yang, C. Y.; Zhou, B.; Meagher, J. L.; Chinnaswamy, K.; Stuckey, J. A.; Wang, S. Structure-based design of gamma-carboline analogues as potent and specific BET bromodomain inhibitors J. Med. Chem. 2015, 58, 4927-4939 10.1021/acs.jmedchem.5b00613
130. Slassi, A.; Dove, P. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins. WO2016123709, 2016.
131. Norris, D. J.; Dellucca, G. V.; Gavai, A. V.; Quesnelle, C. A.; Gill, P.; O'malley, D.; Vaccaro, W.; lEE, F. Y.; Debenedetto, M. V.; Degnan, A. P.; Fang, H.; Hill, M. D.; Huang, H.; Schmitz, W. D.; Starrett, J. E.; Han, W.; Tokarski, J. S.; Mandal, S. K. Tricyclic compounds as anticancer agents. WO2015100282, 2015.
132. Foster, A. B. Deuterium isotope effects in studies of drug metabolism Trends Pharmacol. Sci. 1984, 5, 524-527 10.1016/0165-6147(84)90534-0
133. Timmins, G. S. Deuterated drugs: where are we now? Expert Opin. Ther. Pat. 2014, 24, 1067-1075 10.1517/13543776.2014.943184
134. Hay, D.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Philpott, M.; Picaud, S.; Hewings, D. S.; Uttakar, S.; Heightman, T. D.; Conway, S. J.; Knapp, S.; Brennan, P. E. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains MedChemComm 2013, 4, 140-144 10.1039/C2MD20189E
135. Ren, B.; Zhou, C.; Wang, H. Substituted 5-(3,5-dimethylisoxazole-4-yl)indoline-2-ones. WO2014173241, 2014.
136. Aktoudianakis, E.; Chin, G.; Corkey, B. K.; Elbel, J. D.; Jiang, K.; Kobayashi, R.; Martinez, T.; Metobo, T. R.; Mish, S. E.; Shevick, M.; Sperandio, S.; Yang, D.; Zablocki, H. J. Benzimidazolone derivatives as bromodomain inhibitors. WO2014160873, 2014.
137. Engelhardt, H.; Gianni, D.; Mantoulidis, A.; Smethurst, C. Indolinone analogues as BRD4 inhibitors. WO2014154760, 2014.
138. Smethurst, C.; Engelhardt, H.; Gianni, D.; Reiser, U. Dihydroquinazolinone analogues as BRD4 inhibitors. WO2014154762, 2014.
139. Bogdan, A.; Kati, W. M.; Mcdaniel, K. F.; Park, C. H.; Sheppard, G. S.; Wang, L. Bromodomain inhibitors. US20150158873, 2015.
140. Wang, L.; Frey, R. R.; Hansen, T. M.; Liu, D.; Mcclellan, W. J.; Mcdaniel, K. F.; Pratt, J. K.; Wada, C. K. Bromodomain inhibitors. WO2015085925, 2015.
141. Engelhardt, H. Benzimidazole derivatives. WO2015169962, 2015.
142. Engelhardt, H.; Martin, L.; Smethurst, C. Pyridinones. WO2015022332, 2015.
143. Wang, L.; Dai, Y.; Holms, J.; Liu, D.; Mcclellan, W.; Mcdaniel, K.; Hasvold, L.; Fidanze, S. D.; Sheppard, G.; Marjanovic, J. Bromodomain inhibitors. WO2014206150, 2014.
144. Abdel-Magid, A. F. Inhibitors of BRD4 as potential cancer therapy ACS Med. Chem. Lett. 2016, 7, 728-729 10.1021/acsmedchemlett.6b00259
145. Engelhardt, H.; Gianni, D.; Smethurst, C. Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors. US20160129001, 2016.
146. Engelhardt, H. Triazolopyrazine derivatives as BRD4 inhibitors. WO2015067770, 2015.
147. Bordas, V.; Cotesta, S.; Guagnano, V.; Rueeger, H.; Vaupel, A. Pyrazolopyrrolidine derivatives and their use in the treatment of disease. US20140349990, 2014.
148. Blank, J.; Bold, G.; Bordas, V.; Cotesta, S.; Guagnano, V.; Rueger, H.; Vaupel, A. Pyrrolopyrrolone derivatives and their use as BET inhibitors. WO2015075665, 2015.
149. Gosmini, R.; Nguyen, V. L.; Toum, J.; Simon, C.; Brusq, J. M.; Krysa, G.; Mirguet, O.; Riou-Eymard, A. M.; Boursier, E. V.; Trottet, L.; Bamborough, P.; Clark, H.; Chung, C. W.; Cutler, L.; Demont, E. H.; Kaur, R.; Lewis, A. J.; Schilling, M. B.; Soden, P. E.; Taylor, S.; Walker, A. L.; Walker, M. D.; Prinjha, R. K.; Nicodeme, E. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor J. Med. Chem. 2014, 57, 8111-8131 10.1021/jm5010539
150. Chung, C. W.; Dean, A. W.; Woolven, J. M.; Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 2012, 55, 576-586 10.1021/jm201320w
151. Wyce, A.; Ganji, G.; Smitheman, K. N.; Chung, C. W.; Korenchuk, S.; Bai, Y.; Barbash, O.; Le, B.; Craggs, P. D.; McCabe, M. T.; Kennedy-Wilson, K. M.; Sanchez, L. V.; Gosmini, R. L.; Parr, N.; McHugh, C. F.; Dhanak, D.; Prinjha, R. K.; Auger, K. R.; Tummino, P. J. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models PLoS One 2013, 8, e72967 10.1371/journal.pone.0072967
152. Amans, D.; Atkinson, S. J.; Harrison, D. J.; Hirst, D. J.; Law, R. P.; Lindon, M.; Preston, A.; Seal, J. T.; Wellaway, C. R. 2,3-Disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors. WO2014140076, 2014.
153. Bair, K. W.; Herbertz, T.; Kauffman, G. S.; Kayser-Bricker, K. J.; Luke, G. P.; Martin, M. W.; Millan, D. S.; Schiller, S. R.; Talbot, A. C. Tetrahydroquinoline composition as BET bromodomain inhibitors. WO2015074064, 2015.
154. Schmees, N.; Haendler, B.; Stockigt, D.; Gallenkamp, D.; Bissell, R. A.; Bouglas, R. A. Modified BET-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones. WO2015004075, 2015.
155. Fish, P. V.; Filippakopoulos, P.; Bish, G.; Brennan, P. E.; Bunnage, M. E.; Cook, A. S.; Federov, O.; Gerstenberger, B. S.; Jones, H.; Knapp, S.; Marsden, B.; Nocka, K.; Owen, D. R.; Philpott, M.; Picaud, S.; Primiano, M. J.; Ralph, M. J.; Sciammetta, N.; Trzupek, J. D. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit J. Med. Chem. 2012, 55, 9831-9837 10.1021/jm3010515
156. Xue, X.; Zhang, Y.; Liu, Z.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu, Y. Discovery of benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: Structure-based virtual screening, optimization, and biological evaluation J. Med. Chem. 2016, 59, 1565-1579 10.1021/acs.jmedchem.5b01511
157. Hasvold, L. A.; Pratt, J. K.; Mcdaniel, K. F.; Sheppard, G. S.; Liu, D.; Elmore, S. W.; Hubbard, R. D. Pyrrole-3-carboxamide bromodomain inhibitors. US20140275079, 2014.
158. Hasvold, L. A.; Liu, D.; Park, C. H.; Pratt, J. K.; Sheppard, G. S.; Wang, L. Isoindolone derivatives. WO2013158952, 2013.
159. Lucas, X.; Wohlwend, D.; Hugle, M.; Schmidtkunz, K.; Gerhardt, S.; Schule, R.; Jung, M.; Einsle, O.; Gunther, S. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading Angew. Chem., Int. Ed. 2013, 52, 14055-14059 10.1002/anie.201307652
160. Hugle, M.; Lucas, X.; Weitzel, G.; Ostrovskyi, D.; Breit, B.; Gerhardt, S.; Einsle, O.; Gunther, S.; Wohlwend, D. 4-Acyl pyrrole derivatives yield novel vectors for designing inhibitors of the acetyl-lysine recognition site of BRD4(1) J. Med. Chem. 2016, 59, 1518-1530 10.1021/acs.jmedchem.5b01267
161. Zhao, L.; Cao, D.; Chen, T.; Wang, Y.; Miao, Z.; Xu, Y.; Chen, W.; Wang, X.; Li, Y.; Du, Z.; Xiong, B.; Li, J.; Xu, C.; Zhang, N.; He, J.; Shen, J. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain J. Med. Chem. 2013, 56, 3833-3851 10.1021/jm301793a
162. Zhao, L.; Wang, Y.; Cao, D.; Chen, T.; Wang, Q.; Li, Y.; Xu, Y.; Zhang, N.; Wang, X.; Chen, D.; Chen, L.; Chen, Y. L.; Xia, G.; Shi, Z.; Liu, Y. C.; Lin, Y.; Miao, Z.; Shen, J.; Xiong, B. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization J. Med. Chem. 2015, 58, 1281-1297 10.1021/jm501504k
163. Toure, M.; Crews, C. M. Small-molecule PROTACS: new approaches to protein degradation Angew. Chem., Int. Ed. 2016, 55, 1966-1973 10.1002/anie.201507978
164. Buckley, D. L.; Crews, C. M. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system Angew. Chem., Int. Ed. 2014, 53, 2312-2330 10.1002/anie.201307761
165. Raina, K.; Crews, C. M. Chemical inducers of targeted protein degradation J. Biol. Chem. 2010, 285, 11057-11060 10.1074/jbc.R109.078105
166. Bulatov, E.; Ciulli, A. Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation Biochem. J. 2015, 467, 365-386 10.1042/BJ20141450
167. Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.; Bradner, J. E. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015, 348, 1376-1381 10.1126/science.aab1433
168. Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J. D.; Crew, A. P.; Coleman, K.; Crews, C. M. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 Chem. Biol. 2015, 22, 755-763 10.1016/j.chembiol.2015.05.009
169. Zengerle, M.; Chan, K. H.; Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4 ACS Chem. Biol. 2015, 10, 1770-1777 10.1021/acschembio.5b00216
170. Tanaka, M.; Roberts, J. M.; Seo, H. S.; Souza, A.; Paulk, J.; Scott, T. G.; DeAngelo, S. L.; Dhe-Paganon, S.; Bradner, J. E. Design and characterization of bivalent BET inhibitors Nat. Chem. Biol. 2016, 12, 1089-1096 10.1038/nchembio.2209
171. Rhyasen, G. W.; Hattersley, M. M.; Yao, Y.; Dulak, A.; Wang, W.; Petteruti, P.; Dale, I. L.; Boiko, S.; Cheung, T.; Zhang, J.; Wen, S.; Castriotta, L.; Lawson, D.; Collins, M.; Bao, L.; Ahdesmaki, M. J.; Walker, G.; O'Connor, G.; Yeh, T. C.; Rabow, A. A.; Dry, J. R.; Reimer, C.; Lyne, P.; Mills, G. B.; Fawell, S. E.; Waring, M. J.; Zinda, M.; Clark, E.; Chen, H. AZD5153: A novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies Mol. Cancer Ther. 2016, 15, 2563-2574 10.1158/1535-7163.MCT-16-0141
172. Martin, M. P.; Olesen, S. H.; Georg, G. I.; Schonbrunn, E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains ACS Chem. Biol. 2013, 8, 2360-2365 10.1021/cb4003283
173. Ember, S. W.; Zhu, J. Y.; Olesen, S. H.; Martin, M. P.; Becker, A.; Berndt, N.; Georg, G. I.; Schonbrunn, E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 2014, 9, 1160-1171 10.1021/cb500072z
174. Steegmaier, M.; Hoffmann, M.; Baum, A.; Lenart, P.; Petronczki, M.; Krssak, M.; Gurtler, U.; Garin-Chesa, P.; Lieb, S.; Quant, J.; Grauert, M.; Adolf, G. R.; Kraut, N.; Peters, J. M.; Rettig, W. J. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr. Biol. 2007, 17, 316-322 10.1016/j.cub.2006.12.037
175. Ciceri, P.; Muller, S.; O'Mahony, A.; Fedorov, O.; Filippakopoulos, P.; Hunt, J. P.; Lasater, E. A.; Pallares, G.; Picaud, S.; Wells, C.; Martin, S.; Wodicka, L. M.; Shah, N. P.; Treiber, D. K.; Knapp, S. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nat. Chem. Biol. 2014, 10, 305-312 10.1038/nchembio.1471
176. Chen, L.; Yap, J. L.; Yoshioka, M.; Lanning, M. E.; Fountain, R. N.; Raje, M.; Scheenstra, J. A.; Strovel, J. W.; Fletcher, S. BRD4 structure-activity relationships of dual PLK1 kinase/BRD4 bromodomain inhibitor BI-2536 ACS Med. Chem. Lett. 2015, 6, 764-769 10.1021/acsmedchemlett.5b00084
177. Dittmann, A.; Werner, T.; Chung, C. W.; Savitski, M. M.; Falth Savitski, M.; Grandi, P.; Hopf, C.; Lindon, M.; Neubauer, G.; Prinjha, R. K.; Bantscheff, M.; Drewes, G. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains ACS Chem. Biol. 2014, 9, 495-502 10.1021/cb400789e
178. Allen, B. K.; Mehta, S.; Ember, S. W.; Schonbrunn, E.; Ayad, N.; Schurer, S. C. Large-scale computational screening identifies first in class multitarget inhibitor of EGFR kinase and BRD4 Sci. Rep. 2015, 5, 16924 10.1038/srep16924
179. Zhang, Z.; Hou, S.; Chen, H.; Ran, T.; Jiang, F.; Bian, Y.; Zhang, D.; Zhi, Y.; Wang, L.; Zhang, L.; Li, H.; Zhang, Y.; Tang, W.; Lu, T.; Chen, Y. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors Bioorg. Med. Chem. Lett. 2016, 26, 2931-2935 10.1016/j.bmcl.2016.04.034
180. Zhang, G.; Plotnikov, A. N.; Rusinova, E.; Shen, T.; Morohashi, K.; Joshua, J.; Zeng, L.; Mujtaba, S.; Ohlmeyer, M.; Zhou, M. M. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains J. Med. Chem. 2013, 56, 9251-9264 10.1021/jm401334s
181. Galdeano, C.; Ciulli, A. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology Future Med. Chem. 2016, 8, 1655-1680 10.4155/fmc-2016-0059
182. Raux, B.; Voitovich, Y.; Derviaux, C.; Lugari, A.; Rebuffet, E.; Milhas, S.; Priet, S.; Roux, T.; Trinquet, E.; Guillemot, J. C.; Knapp, S.; Brunel, J. M.; Fedorov, A. Y.; Collette, Y.; Roche, P.; Betzi, S.; Combes, S.; Morelli, X. Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins J. Med. Chem. 2016, 59, 1634-1641 10.1021/acs.jmedchem.5b01708
183. Devaiah, B. N.; Lewis, B. A.; Cherman, N.; Hewitt, M. C.; Albrecht, B. K.; Robey, P. G.; Ozato, K.; Sims, R. J., 3rd; Singer, D. S. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 6927-6932 10.1073/pnas.1120422109
184. Baud, M. G.; Lin-Shiao, E.; Cardote, T.; Tallant, C.; Pschibul, A.; Chan, K. H.; Zengerle, M.; Garcia, J. R.; Kwan, T. T.; Ferguson, F. M.; Ciulli, A. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes Science 2014, 346, 638-641 10.1126/science.1249830
185. Garnier, J. M.; Sharp, P. P.; Burns, C. J. BET bromodomain inhibitors: a patent review Expert Opin. Ther. Pat. 2014, 24, 185-199 10.1517/13543776.2014.859244
186. Jung, M.; Philpott, M.; Muller, S.; Schulze, J.; Badock, V.; Eberspacher, U.; Moosmayer, D.; Bader, B.; Schmees, N.; Fernandez-Montalvan, A.; Haendler, B. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1 J. Biol. Chem. 2014, 289, 9304-9319 10.1074/jbc.M113.523019
187. Sharp, P. P.; Garnier, J.-M.; Huang, D. C. S.; Burns, C. J. Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition MedChemComm 2014, 5, 1834-1842 10.1039/C4MD00182F
188. Duffy, B. C.; Liu, S.; Martin, G. S.; Wang, R.; Hsia, M. M.; Zhao, H.; Guo, C.; Ellis, M.; Quinn, J. F.; Kharenko, O. A.; Norek, K.; Gesner, E. M.; Young, P. R.; McLure, K. G.; Wagner, G. S.; Lakshminarasimhan, D.; White, A.; Suto, R. K.; Hansen, H. C.; Kitchen, D. B. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design Bioorg. Med. Chem. Lett. 2015, 25, 2818-2823 10.1016/j.bmcl.2015.04.107
189. Zhao, H.; Gartenmann, L.; Dong, J.; Spiliotopoulos, D.; Caflisch, A. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking Bioorg. Med. Chem. Lett. 2014, 24, 2493-2496 10.1016/j.bmcl.2014.04.017
190. Noguchi-Yachide, T.; Sakai, T.; Hashimoto, Y.; Yamaguchi, T. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors Bioorg. Med. Chem. 2015, 23, 953-959 10.1016/j.bmc.2015.01.022
191. Vidler, L. R.; Filippakopoulos, P.; Fedorov, O.; Picaud, S.; Martin, S.; Tomsett, M.; Woodward, H.; Brown, N.; Knapp, S.; Hoelder, S. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening J. Med. Chem. 2013, 56, 8073-8088 10.1021/jm4011302
192. Chen, H.; Zhou, X.; Wang, A.; Zheng, Y.; Gao, Y.; Zhou, J. Evolutions in fragment-based drug design: the deconstruction-reconstruction approach Drug Discovery Today 2015, 20, 105-113 10.1016/j.drudis.2014.09.015
193. Herait, P. E.; Berthon, C.; Thieblemont, C.; Raffoux, E.; Magarotto, V.; Stathis, A.; Thomas, X.; Leleu, X.; Gomez-Roca, C.; Odore, E.; Roumier, C.; Bourdel, F.; Quesnel, B.; Zucca, E.; Michallet, M.; Recher, C.; Cvitkovic, E.; Rezai, K.; Preudhomme, C.; Facon, T.; Palumbo, A.; Dombret, H. Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies Cancer Res. 2014, 74, CT231-CT231 10.1158/1538-7445.AM2014-CT231
194. Fong, C. Y.; Gilan, O.; Lam, E. Y.; Rubin, A. F.; Ftouni, S.; Tyler, D.; Stanley, K.; Sinha, D.; Yeh, P.; Morison, J.; Giotopoulos, G.; Lugo, D.; Jeffrey, P.; Lee, S. C.; Carpenter, C.; Gregory, R.; Ramsay, R. G.; Lane, S. W.; Abdel-Wahab, O.; Kouzarides, T.; Johnstone, R. W.; Dawson, S. J.; Huntly, B. J.; Prinjha, R. K.; Papenfuss, A. T.; Dawson, M. A. BET inhibitor resistance emerges from leukaemia stem cells Nature 2015, 525, 538-542 10.1038/nature14888
195. Rathert, P.; Roth, M.; Neumann, T.; Muerdter, F.; Roe, J. S.; Muhar, M.; Deswal, S.; Cerny-Reiterer, S.; Peter, B.; Jude, J.; Hoffmann, T.; Boryn, L. M.; Axelsson, E.; Schweifer, N.; Tontsch-Grunt, U.; Dow, L. E.; Gianni, D.; Pearson, M.; Valent, P.; Stark, A.; Kraut, N.; Vakoc, C. R.; Zuber, J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition Nature 2015, 525, 543-547 10.1038/nature14898
196. Shu, S.; Lin, C. Y.; He, H. H.; Witwicki, R. M.; Tabassum, D. P.; Roberts, J. M.; Janiszewska, M.; Huh, S. J.; Liang, Y.; Ryan, J.; Doherty, E.; Mohammed, H.; Guo, H.; Stover, D. G.; Ekram, M. B.; Peluffo, G.; Brown, J.; D'Santos, C.; Krop, I. E.; Dillon, D.; McKeown, M.; Ott, C.; Qi, J.; Ni, M.; Rao, P. K.; Duarte, M.; Wu, S. Y.; Chiang, C. M.; Anders, L.; Young, R. A.; Winer, E. P.; Letai, A.; Barry, W. T.; Carroll, J. S.; Long, H. W.; Brown, M.; Liu, X. S.; Meyer, C. A.; Bradner, J. E.; Polyak, K. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Nature 2016, 529, 413-417 10.1038/nature16508
197. Kurimchak, A. M.; Shelton, C.; Duncan, K. E.; Johnson, K. J.; Brown, J.; O'Brien, S.; Gabbasov, R.; Fink, L. S.; Li, Y.; Lounsbury, N.; Abou-Gharbia, M.; Childers, W. E.; Connolly, D. C.; Chernoff, J.; Peterson, J. R.; Duncan, J. S. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer Cell Rep. 2016, 16, 1273-1286 10.1016/j.celrep.2016.06.091
198. Muralidharan, S. V.; Bhadury, J.; Nilsson, L. M.; Green, L. C.; McLure, K. G.; Nilsson, J. A. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells Oncogene 2016, 35, 4689-4697 10.1038/onc.2015.521
199. Amorim, S.; Stathis, A.; Gleeson, M.; Iyengar, S.; Magarotto, V.; Leleu, X.; Morschhauser, F.; Karlin, L.; Broussais, F.; Rezai, K.; Herait, P.; Kahatt, C.; Lokiec, F.; Salles, G.; Facon, T.; Palumbo, A.; Cunningham, D.; Zucca, E.; Thieblemont, C. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study Lancet Haematol. 2016, 3, e196-204 10.1016/S2352-3026(16)00021-1
200. Amarnath Praphakar, R.; Munusamy, M. A.; Sadasivuni, K. K.; Rajan, M. Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers Int. J. Pharm. 2016, 513, 628-635 10.1016/j.ijpharm.2016.09.080